Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL). After the treatment of standard chemotherapy R-CHOP regimen, approximately 40% of DLBCL patients fail to respond to treatment or show progress of the disease. At the 61st American Society of Hematology Annual Meeting, multiple studies reported the latest treatment progress of DLBCL, including improving the prognosis of newly diagnosed patients and providing more treatment options for relapsed/refractory DLBCL patients. Key words: Lymphoma, large B-cell, diffuse; Recurrence; Refractory; Drug therapy, combination; Molecular targeted therapy; Immunotherapy
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
